­
­
­
­

Inventi Impact: Infectious Diseases & Immunology

Articles

  • Inventi:hidi/31720/20
    Relationship Between Serum Inhibitory Activity for IgE and Efficacy of Artemisia Pollen Subcutaneous Immunotherapy for Allergic Rhinitis: A Preliminary Self-Controlled Study
    Research 2020 : July - September
    Wenping Wang, Jinshu Yin, Xueyan Wang, Tingting Ma, Tianfei Lan, Qingkun Song, Yifan Guo

    Background: Biomarkers of clinical efficacy for subcutaneous immunotherapy (SCIT) on allergic rhinitis (AR) have\nnot been identified yet. This study aims to assess the clinical relevance of serum inhibitory activity for IgE by the\nmethod of enzyme-linked immunosorbent facilitated antigen binding (ELIFAB) during SCIT for Artemisia-sensitized AR\npatients.\nMethods: 19 AR patients were studied who had undergone Artemisia-specific SCIT for more than 8 months\n(19.68 months on average, ranging from 9 to 33 months). Peripheral bloods were collected before and after treatment.\nThe serum inhibitory activity for IgE was tested by ELIFAB and the level of Artemisia-specific IgG4 (Artemisia-sIgG4)\nwas determined by ELISA. Clinical improvement was evaluated based on the symptom scores and rescue medication\nuse (SMS). The 2-tailed Wilcoxon signed-rank test and the Spearman rank test (two-tailed) were used to analyze data\nby using SPSS 20.0, with P values of less than 0.05 considered as significant..................

    How to Cite this Article
    Attribution/ CC Compliant Citation: Wang, Wenping, et al. \"Relationship between serum inhibitory activity for IgE and efficacy\nof Artemisia pollen subcutaneous immunotherapy for allergic rhinitis: a preliminary self-controlled study.\" Allergy, Asthma &\nClinical Immunology 16.1 (2020): 1-9.\nhttps://doi.org/10.1186/s13223-020-0416-4\nhttp://creativecommons.org/licenses/by/4.0/\n\nSome formatting elements, header, footer, logos, dates and pagination were modified while adapting this article.
    Download Full Text